Mawson Infrastructure Group a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES). Co. has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjogren's syndrome (Sjogren's). LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and ophthalmological symptoms of Sjogren's and in the Netherlands for the treatment of DES and protection from dry eye as a result of Sjogren's. We show 12 historical shares outstanding datapoints in our coverage of MIGI's shares outstanding history.
Understanding the changing numbers of MIGI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MIGI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MIGI by allowing them to research MIGI shares outstanding history
as well as any other stock in our coverage universe. |
Free MIGI Email Alerts:
Video: Shares Outstanding Importance
